Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

    NEXT STORY
    Jackson Memorial Hospital gives Philips Enterprise Monitoring as a Service model high marks for satisfaction and efficiency
    PREV STORY
    I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

    Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease ...

    author_avatar
    NASDAQ Market News

    CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity

    author_avatar
    NASDAQ Market News

    Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

    author_avatar
    NASDAQ Market News